FDA warned MexHealth LLC d/b/a Al Natural E-Shop that its Ossos-Sans supplement is an unapproved, misbranded drug containing hidden diclofenac and methocarbamol.
What happened
FDA reviewed the company's website in April 2024 and July 2024 and obtained samples and labeling of Ossos-Sans. Laboratory analysis found the product contained undeclared diclofenac and methocarbamol. The website and labeling marketed it as a dietary supplement for arthritis, osteoporosis, inflammation, and other conditions.
What FDA found
The product is a new drug without an FDA-approved application, so it cannot be legally sold across state lines.
FD&C Act §§ 505(a), 301(d), 21 U.S.C. §§ 355(a), 331(d)The labeling does not disclose that the product contains diclofenac and methocarbamol, making it misbranded.
FD&C Act § 502(a), 21 U.S.C. § 352(a); § 201(n), 21 U.S.C. § 321(n)The product is labeled as a dietary supplement, but it contains diclofenac, a drug ingredient approved before it was marketed as a supplement, so it falls outside the dietary supplement definition.
FD&C Act § 201(ff)(3)(B)(i), 21 U.S.C. § 321(ff)(3)(B)(i)The label claims the product treats arthritis, osteoporosis, inflammation, fractures, and other conditions, which shows it is intended as a drug.
FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1)The product is misbranded because its labeling fails to reveal material facts about the hidden drug ingredients.
FD&C Act § 502(a), 21 U.S.C. § 352(a)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt with the specific corrective steps, how it will prevent recurrence, related documentation, or its reasoning and evidence if it believes there is no violation.
Who should pay attention
- online shoppers buying arthritis or pain supplements
- retailers and online marketplaces selling supplements
- supplement brands and distributors relying on supplier labels
This is a summary. Read the original letter on fda.gov.